# Cleveland Alzheimers Disease Research Center

> **NIH NIH P30** · CLEVELAND CLINIC LERNER COM-CWRU · 2022 · $3,078,496

## Abstract

PROJECT SUMMARY
 The Cleveland Alzheimer's Disease Research Center (CADRC) is a collaborative effort of physicians
and investigators from Case Western Reserve University (CWRU), Cleveland Clinic Foundation (CCF),
MetroHealth System (MHS), University Hospitals (UH), and the Louis Stokes Cleveland VA Medical Center
(LSCVAMC), to foster excellence in research and facilitate discovery as an established National Institute on
Aging (NIA) funded Alzheimer's Disease Research Center. The CADRC represents a rich clinical and research
community and an estimated 220,000 Ohioans who suffer from Alzheimer's disease (AD) or AD-related
dementias (ADRD). The CADRC has 8 Cores and a Research Education Component designed to create the
foundation that will enhance the research efforts of the Northeast Ohio AD/ADRD research community, as well
as add unique value to the national Alzheimer's Disease Research Centers (ADRC) program and other
national and international research programs. The CADRC is focused on participants that will help us
understand the pathobiology of clinical and pathological heterogeneity observed in dementia including atypical
and amnestic AD, dementia with Lewy bodies, cognitively normal individuals with different levels of genetic risk
for AD, and diversity of participant populations (Clinical and Outreach, Recruitment, and Engagement Cores).
To support the CADRC goals, the focus will be on deep phenotyping of participants with longitudinal and
systematic cognitive, behavioral and motor characterization (Clinical Core), genetic and biofluid biomarker
collection and analysis (Biomarker Core), imaging (Neuroimaging Core), and autopsy after death
(Neuropathology Core). Results will be shared with the research community in a timely and regular manner to
allow other investigators to benefit from the CADRC efforts (Data Management and Statistics Core). In
addition, the CADRC will train the next generation of investigators utilizing a rigorous and well-designed
Research Education Component, support translation of new laboratory findings through the Translational
Therapeutics Core, and support high risk/high gain projects through the developmental program as a part of
the Administrative Core. The ultimate goals are to advance the precision medicine approach to dementia
diagnosis and treatment, support the development of early stage investigators, assist all stages of investigators
with tools for performing human-based research, and better engage underrepresented populations in
AD/ADRD research.

## Key facts

- **NIH application ID:** 10474587
- **Project number:** 5P30AG072959-02
- **Recipient organization:** CLEVELAND CLINIC LERNER COM-CWRU
- **Principal Investigator:** JAMES Bruce LEVERENZ
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $3,078,496
- **Award type:** 5
- **Project period:** 2021-09-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10474587

## Citation

> US National Institutes of Health, RePORTER application 10474587, Cleveland Alzheimers Disease Research Center (5P30AG072959-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10474587. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*